TSHA Completes Dosing
Taysha Gene Therapies completes dosing in REVEAL pivotal trial and reports longer-term clinical data from Part A of REVEAL Phase 1/2 trials for TSHA-102
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.